Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03065881Not ApplicableCompleted

RETeval All Comers Trial (REACT)

Role: lead

NCT02466607Not ApplicableCompleted

Study of Stimulus Parameters in Flicker Electroretinogram (ERG)

Role: lead

NCT01950663Not ApplicableCompleted

RETeval Study for Diabetic Retinopathy

Role: collaborator

All 3 trials loaded